Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of multispecific CMV/EBV/AdV T cells for chemo-refractory viral infections after allogeneic HSCT
NL-OMON54824Phase 3Recruiting
- Sponsor
- LMU Klinikum
- Start
- Mar 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV), Epstein-Barr virus infection and adenoviral infection comparing Multivirus-specific T cells with Placebo (2 arms). Primary endpoints: Viral clearance and Disease progression. Started Mar 2020; status: recruiting.
02
Drugs
HLA-matched multivirus-specific T cells
03
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infection
Beyond the preview
Go deeper on NL-OMON54824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54824.